Description: These stocks have been raising their dividend payments annually for well over a decade, and they pay more than twice the S&P 500 average.

Description: AbbVie (ABBV) shares are holding steady as investors assess the company’s ongoing performance following recent earnings. With key drugs still leading the portfolio, many are watching how AbbVie manages steady growth in a competitive sector. See our latest analysis for AbbVie. AbbVie’s share price has steadily climbed this year, with a year-to-date return of nearly 27%. The company’s recent updates have not slowed its momentum, as investor confidence continues to build. This is reflected in an...

Description: SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s disease (CD) and now for ulcerative colitis (UC), supported by evidence from pivotal phase 3 clinical trials including MOTIVATE, ADVANCE, FORTIFY (for CD), and INSPIRE, COMMAND (for UC).1,2AbbVie concludes letter of intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding SKYRIZI® f

Description: Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.

Description: Most of the market was feasting on another helping of Thanksgiving week gains on Wednesday, but enterprise software and health care stocks were missing out on the celebration. Workday was the biggest laggard in the S&P 500 and among the fewer than 90 stocks in the index that were trading lower on Wednesday. Salesforce, another major player in enterprise software, reports quarterly results a week from today.

Description: ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.

Description: AbbVie has outperformed the Nasdaq over the past year, and analysts are moderately optimistic about the stock’s prospects.

Description: The Centers for Medicare & Medicaid Services said Tuesday it expects to achieve net savings of 44%,

Description: Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.

Description: National competition, in collaboration with adMare BioInnovations, demonstrates AbbVie's commitment to a thriving biotech ecosystem in Quebec One biotech will receive a year of laboratory and office space including access to shared equipment and services at no cost at the adMare Innovation Centre in Montreal, as well as access to AbbVie's scientific and business executives support and mentorshipApplications will be accepted until February 20, 2026. MONTREAL, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tod

Description: Analysts have recently nudged AbbVie's consensus price target upward, rising slightly from $241.29 to $243.55 as updated sentiment filters through the market. This shift reflects increased optimism driven by strong performance in key growth areas and strategic business moves. Stay tuned to find out how investors can stay informed on evolving perspectives and future updates in AbbVie’s dynamic story. Analyst Price Targets don't always capture the full story. Head over to our Company Report to...

Description: AbbVie recently received full FDA approval for EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide for the treatment of adults with relapsed or refractory follicular lymphoma, following robust Phase 3 results showing significant improvement over standard of care. This landmark regulatory milestone addresses an unmet need in a challenging lymphoma type, potentially expanding AbbVie's reach in oncology and advancing treatment standards for patients with limited...

Description: AbbVie (NYSE: ABBV) will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025. Management will participate in a fireside chat at 7:30 a.m. Central time.

Description: The industry is showing enthusiasm for novel technologies that improve safety and carry innovation potential including in vivo CAR-Ts.

Description: Investors should be able to count on steady dividends from these great stocks.

Description: In the last year, many AbbVie Inc. ( NYSE:ABBV ) insiders sold a substantial stake in the company which may have...

Description: JPM shows solid operational strength as analysts highlight its NII outlook, fee pressures and expense trajectory through 2027.

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to

Description: JPMorgan's year-to-date gains, NII growth outlook and investment banking pipeline headline today's standout Zacks research picks.

Description: Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.

Description: Ironwood gains momentum as rising U.S. demand for Linzess drives strong profit growth during the third quarter.

Description: LLY's expanding AI alliances highlight how pharma-tech partnerships are transforming healthcare and lifting key sector ETFs like XLV.

Description: ANI Pharmaceuticals' rare disease surge, led by Cortrophin Gel, drives major 2025 revenue gains despite softer ophthalmology sales.

Description: Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.

Description: Trying to build a portfolio that can survive recessions, inflation, and market volatility is one of the biggest challenges any investor can face. Unexpected market moves are hard to predict, and if you could make such predictions, not only would you be rich, but people would be throwing money at you, literally, to invest it ... 2 Dividend Stocks to Hold Through Any Market Cycle

Description: The global metrorrhagia market is expanding due to an increasing prevalence of gynecological disorders like uterine fibroids and hormonal imbalances, fueling the demand for effective treatments. Despite challenges such as high diagnostic costs and limited awareness, advancements in hormonal and non-hormonal therapies are driving patient adoption. Key developments include targeted drug formulations, innovative surgical techniques, and emerging therapies like selective progesterone receptor modula

Description: ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.

Description: Liver failure is a critical condition where the liver loses its ability to detoxify, synthesize proteins, and regulate biochemical processes. It can result from hepatitis, alcohol abuse, NAFLD, autoimmune diseases, or toxins. Key symptoms include jaundice, encephalopathy, ascites, and bleeding. The global liver failure market is expanding due to rising disease prevalence, enhanced healthcare access, and diversified therapies. Innovations in transplantation, artificial liver systems, and pharmaco

Description: AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Description: Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Description: As the U.S. stock market experiences a period of volatility, with major indices like the S&P 500 and Dow Jones Industrial Average facing consecutive declines, investors are keenly observing the impact of high valuations in sectors such as technology. Amidst these fluctuations, identifying stocks that are potentially trading below their intrinsic value can offer opportunities for those looking to navigate current market conditions wisely.

Description: A bipartisan report warned Congress about China’s growing control over the pharmaceutical supply chain. Elsewhere, Alkermes sweetened its bid for Avadel and Moderna is investing $140 million in U.S. drug production.

Description: Wondering if AbbVie is a smart buy at today's price? You're not the only one. Let's dig into the numbers to find out how the market might be valuing the stock right now. AbbVie’s share price has jumped 7.0% in the past week and surged 30.4% year-to-date, putting its performance firmly in the spotlight and hinting at shifting investor sentiment. This momentum hasn’t come out of nowhere. Investors are reacting to positive developments from AbbVie’s drug pipeline and several high-profile FDA...

Description: Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index up 0.3% and the Heal

Description: AbbVie (NYSE: ABBV) today announced that EPKINLY® (epcoritamab-bysp), a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab and lenalidomide (EPKINLY + R2) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). This approval of EPKINLY is based on results from the pivotal Phase 3 EPCORE® FL-1 study that evaluated fixed duration EPKINLY + R2 compared to st

Description: The global cervical dystonia market is thriving, driven by increased disease prevalence, advancements in neuromodulation techniques, and heightened awareness of movement disorders. Key factors include the widespread adoption of botulinum toxin therapies and deep brain stimulation for refractory cases, along with innovations in drug formulations. While barriers such as diagnosis delays and treatment cost persist, strategic efforts by industry leaders like Ipsen and AbbVie are shaping market dynam

Description: ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.

Description: It's no reason to stay up at night.

Description: AbbVie (NYSE: ABBV) announced today that a new 6-month 45mg LUPRON DEPOT® (leuprolide acetate for extended-release injectable suspension) strength has received Health Canada approval for the treatment of advanced prostate cancer. LUPRON DEPOT is now available in four dosing options: 7.5 mg (1-Month), 22.5 mg (3-Month), 30 mg (4-Month), and 45 mg (6-Month).1 LUPRON DEPOT was initially approved by Health Canada for advanced prostate cancer in 1989, providing 36 years of proven clinical use in Cana

Description: AbbVie Inc. ( NYSE:ABBV ) has announced that it will be increasing its dividend from last year's comparable payment on...

Description: These stocks pay income that investors can count on over the long run.

Description: AbbVie (ABBV) is back in the spotlight after announcing strong quarterly results and a 6% dividend increase. The company also made waves by shifting strategy away from its Calico Life Sciences partnership and updating investors on several fronts. See our latest analysis for AbbVie. AbbVie shares have outpaced much of the market lately, supported by upbeat earnings, a hefty dividend increase, and high-profile strategic refocusing. With a 29% year-to-date share price return and a standout 46%...

Description: AbbVie (NYSE: ABBV) announced today the launch of Second Winds, a new short film that captures the powerful, deeply personal journeys of three people living with chronic lymphoma leukemia (CLL), a common type of blood cancer effecting hundreds of thousands of people in the United States.1,2 Each person's dynamic story reveals how facing a life-changing diagnosis can bring clarity and purpose, sparking a renewed commitment to staying active and embracing what truly matters in their lives.

Description: Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.

Description: Agentic AI is making its way into pharma marketing — and raising a slew of potential challenges around regulations and ethics.

Description: New insights from Spherix Global Insights reveal strong rheumatologist anticipation for next-generation oral and multi-pathway innovations, including Sotyktu, icotrokinra, and sonelokimab.Exton, PA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The 2025 Market Dynamix™: Psoriatic Arthritis and Ankylosing Spondylitis/Non-Radiographic Axial Spondyloarthritis (EU5) studies from Spherix Global Insights reveal a rapidly evolving treatment landscape, as rheumatologists expand use of next-generation IL-17 and JAK

Description: Insightful Analysis of Robert Bruce (Trades, Portfolio)'s Third Quarter 2025 13F Filing

Description: Ironwood's 110% monthly surge follows upbeat third-quarter results and raised 2025 outlook, powered by increasing Linzess demand.

Description: Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

Description: Wall Street closed mixed on Wednesday, pulled up by healthcare and financial stocks.

Description: Pre-Market Stock Futures: The stock futures are trading lower on Thursday, following another incredible day for the Dow Jones Industrials, while the rotation out of the NASDAQ and into technology is still gaining traction. The DJIA posted a record all-time high, closing at 48,254, up another 327 points or 0.68%. The S&P 500 just barely ... Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More

Description: AbbVie (NYSE: ABBV) today announced the 20 recipients of its second annual AbbVie Migraine Career Catalyst Award™ contest, an initiative that helps people living with migraine pursue their career and professional development goals. Each winner received $2,500 in financial support to invest in opportunities that advance their aspirations, from continued education and training to creating healthier, more supportive work environments.

Description: As National Alzheimer's Awareness Month spotlights new treatments, healthcare ETFs like XLV and VHT might gain fresh investor appeal.

Description: These top dividend payers could enrich a long-term investor's portfolio.

Description: BeOne Medicines is Wednesday's IBD Stock Of The Day. The IBD 50 biotech is breaking out after a record-breaking quarter.

Description: Health care stocks rose late Wednesday afternoon with the NYSE Health Care Index gaining 1.6% and th

Description: Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index and the Health Care Sel

Description: As the Dow Jones Industrial Average reaches new heights amid optimism surrounding a potential end to the U.S. government shutdown, investors are closely watching market fluctuations with mixed performances across major indices. In this environment, identifying stocks that may be undervalued becomes crucial, as these investments could offer opportunities for growth when priced below their intrinsic value.

Description: Precision medicine and next-gen biologics are transforming patient care. Despite cost-related challenges, key players like AbbVie, Johnson & Johnson, and Bristol-Myers Squibb are leading innovations.Dublin, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The "Psoriatic Arthritis Market - A Global and Regional Analysis: Focus on Drug Type and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. The growing prevalence of autoimmune diseases, particularly among individu

Description: ABBV's growth engine keeps humming as Skyrizi and Rinvoq together now power more than 40% of total revenues and drive new market share gains.

Description: Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 Index continued its rally in the third quarter, ending the year-to-date returns at 13.7%. During this period, growth and momentum were key contributors to the […]

Description: Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced it will present data highlighting efficacy, safety and patient-reported outcomes across its portfolio during the 2025 American Society of Dermatologic Surgery (ASDS) Annual Meeting, November 13-16, 2025, in Chicago, Illinois. Oral and video poster presentations, along with expert panels and symposiums, collectively demonstrate Allergan Aesthetics' pioneering scientific research and innovation.

Description: PARMA, Italy, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Chiesi Group today announced it has entered into an exclusive license agreement with Aliada Therapeutics, a wholly owned subsidiary of AbbVie, to advance blood-brain barrier (BBB)-crossing platform technology in lysosomal storage disorders (LSD) to address challenging disease areas with high unmet need. “This agreement underscores our continued commitment to creating potential solutions that target the significant unmet needs in managing cognitive

Description: As the U.S. stock market rebounds amid optimism for a resolution to the prolonged government shutdown, investors are eyeing opportunities within this volatile landscape. In such times, identifying undervalued stocks can be crucial for those looking to capitalize on potential discounts, as these stocks may offer significant value relative to their current trading prices.

Description: As the U.S. stock market navigates a period of mixed performance, with major indices like the S&P 500 and Nasdaq showing slight declines following an early-week rally, investors are closely monitoring developments such as the potential end to the government shutdown. In this environment, identifying stocks that may be undervalued becomes crucial for investors seeking opportunities amid fluctuating tech stock performances and broader market shifts.

Description: Ironwood posts a stellar third-quarter beat with higher revenues and raises 2025 outlook on Linzess-driven strength.

Description: As the United States stock market experiences a surge in optimism due to potential resolutions to the government shutdown, major indices like the Nasdaq, S&P 500, and Dow Jones have posted significant gains. In this environment of renewed investor confidence, identifying undervalued stocks can be particularly advantageous as they may offer opportunities for growth amidst market fluctuations.

Description: AbbVie’s consensus analyst price target has inched up from $237.48 to $241.29, reflecting renewed optimism surrounding the stock’s outlook. This slight boost is attributed to strong sales for core immunology treatments and an extended exclusivity window for Rinvoq, in addition to ongoing strategic developments. As analysts evaluate these catalysts alongside lingering concerns, readers should stay tuned for insights on monitoring evolving opinions and updates in the months ahead. Stay updated...

Description: AbbVie recently reported third-quarter 2025 results, highlighted by a US$1.32 billion year-on-year increase in sales and a US$0.09 quarterly rise in its cash dividend to US$1.73 per share, but also announced a US$847 million intangible asset impairment and a significant drop in net income compared to the previous year. This period illustrates both AbbVie's ongoing emphasis on shareholder returns and the financial pressures from margin compression and asset write-downs. We'll examine how...

Description: With Trump's MFN policy cutting U.S. drug prices, will Pharma ETFs such as IHE, heavily weighted toward Eli Lilly and Novo Nordisk, lose momentum?

Description: CAMBRIDGE, Mass., November 10, 2025--QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that it has appointed Manoj Malhotra, M.D., as chief medical officer (CMO).

Description: Healthcare stocks in the S&P 500 offer an average dividend yield of 1.8%.

Description: These stocks are priced low, have encouraging growth prospects, and also pay dividends.

Description: AbbVie Inc. (NYSE:ABBV) is included among the 15 Best DRIP Stocks to Own Right Now. On November 5, Piper San‍dler​ analyst David Amsellem raised the price target on AbbVie Inc. (NYSE:ABBV) from⁠ $284 to $289 while maintaining an Over‌weight rating on the stock foll‌owing its quarte‍rly re​sults, as reported by The Fly. The analyst att‍ributed […]

Description: As the U.S. stock market navigates a challenging landscape with tech stocks under pressure and major indices experiencing significant losses, investors are keenly observing economic indicators like labor market data and Federal Reserve interest rate decisions. In this environment, identifying undervalued stocks becomes crucial as they may offer potential opportunities for growth amidst broader market volatility.

Description: AbbVie’s third quarter results were marked by strong year-on-year revenue growth, driven primarily by continued momentum in its immunology and neuroscience portfolios. Management pointed to sales growth from Skyrizi and Rinvoq, as well as double-digit expansion in neuroscience products, as key contributors to the performance. However, despite surpassing Wall Street revenue and profit estimates, the market reacted negatively, reflecting heightened concern over a sharp drop in operating margin and

Description: HORSHOLM, DENMARK / ACCESS Newswire / November 6, 2025 /Revenue and earnings for Gubra (CPH:GUBRA) reached record-high levels in the first nine months of 2025. Group revenue and adjusted EBIT amounted to DKK 2.6 billion and DKK 2.3 billion, respectively, ...

Description: The market is expanding due to rising cardiovascular disease prevalence, an aging population, and advancements in treatments like SGLT2 inhibitors. Integration of digital health solutions and personalized medicine are key trends reshaping the landscape, enhancing patient outcomes and quality of life.Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. Co

Description: These stocks aren't popular right now, but their strong underlying businesses make them hot deals to pounce on.

Description: Linzess becomes the first FDA-approved treatment for IBS-C in paediatric patients.

Description: REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the third quarter ended September 30, 2025.

Description: Miramar Capital co-founder and senior portfolio manager, Max Wasserman, joins Morning Brief host Julie Hyman to discuss portfolio diversification and which stocks and sectors are poised to benefit as interest rates continue to come down. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.

Description: AbbVie Inc. (NYSE:ABBV) is one of the stocks Jim Cramer recently commented on. Cramer highlighted the possible change in spending habits of the rich while discussing the stock, as he said: “AbbVie stock is still falling after management talked about slowing medical aesthetic sales. Botox for the face may have finally hit a wall, even […]

Description: AbbVie just increased its dividend by 5.5%, raising the quarterly payout to $1.73 per share starting February 2026, reflecting strong confidence in its long-term growth driven by new drugs like Skyrizi and Rinvoq.

Description: The choroidal neovascularization therapeutics market is expected to further increase due to major drivers, including the rising prevalence of the population, technological advancements, and upcoming therapies such as AbbVie and REGENXBIO’s ABBV-RGX-314, Adverum Biotechnologies’ Ixoberogene soroparvovec, Neuracle Genetics’ NG101, and others, during the forecast period (2025–2034).New York, USA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Choroidal Neovascularization Market to Witness Accelerated Growth Thr

Description: Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Description: WALTHAM, Mass., November 05, 2025--Trinity, a leader in global life sciences commercialization, today announced the release of its 5th Annual TGaS Digital Marketing Competency Report, a three-part series benchmarking the digital marketing presence of more than 150 biopharma brands. The 2025 edition reveals a significant leap forward in the industry’s digital sophistication, with a 19% increase in Proficient brands and a surge of innovation in patient engagement strategies.

Description: Calico Life Sciences LLC (Calico), a biotechnology organization focused on aging and age-related diseases and founded by Alphabet Inc. and Arthur D. Levinson, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABBV-CLS-628, an investigational therapy for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). ABBV-CLS-628, an anti-PAPP-A monoclonal antibody, was developed by Calico in collaboration with AbbVie Inc. The the

Description: As the U.S. stock market experiences a pullback with major indices like the Dow Jones, Nasdaq, and S&P 500 showing declines, investors are increasingly cautious amid mixed earnings reports and fluctuating tech shares. In such an environment, identifying stocks that are trading below their fair value can offer potential opportunities for those looking to invest in assets that may be undervalued by the market.

Description: The hyperlipidemia drugs market is growing due to rising cardiovascular disease prevalence, increasing cholesterol management awareness, and aging populations. Opportunities lie in personalized and combination therapies, digital health integration, non-statin alternatives, and expanding markets in Asia-Pacific. Hyperlipidemia Drugs Market Hyperlipidemia Drugs Market Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The "Hyperlipidemia Drugs Market Report 2025" has been added to ResearchAndMarkets.com's

Description: Pre-Market Futures: The S&P 500 and NASDAQ futures are trading down over 1% on Tuesday, following Palantir’s 6.9% decline despite beating earnings expectations and giving strong forward guidance. Concerns over an AI bubble continue to mount. Tuesday’s sell-off follows a wild start to the week, during which the Dow Jones Industrial Average traded lower due ... Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, AbbVie, Broadcom, CyberArk, Palantir Technologies and More

Description: As the U.S. stock market navigates a mixed landscape, with the Nasdaq gaining momentum from tech deals and the Dow facing headwinds, investors are keenly focused on earnings reports and employment data amid a prolonged government shutdown. In this environment, identifying undervalued stocks becomes crucial for those looking to capitalize on potential opportunities; these stocks are estimated to be trading significantly below their intrinsic value, offering possible long-term benefits amidst...

Description: Healthcare has been an extraordinarily resilient industry to put cash to work in through the years.

Description: BioSpace, the leader in biopharma news and careers, has published its 2026 Best Places to Work list.

Description: Although AbbVie has underperformed the S&P 500 Index over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Description: Pharmaceutical company AbbVie (NYSE:ABBV) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 9.1% year on year to $15.78 billion. Its non-GAAP profit of $1.86 per share was 4.2% above analysts’ consensus estimates.

Description: Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund rose 5.39% (Institutional Shares) in the quarter, compared to a 5.05% gain for the Russell 3000 Health Care Index (benchmark) and an 8.18% gain for the Russell 3000 […]

Description: We recently published 10 Stocks Everyone’s Discussing Amid Latest Earnings Season. AbbVie Inc. (NYSE:ABBV) is one of the stocks everyone’s discussing. Jason Snipe, the Founder and Chief Investment Officer of Odyssey Capital Advisors, recommended investors to “stay long” AbbVie Inc (NYSE:ABBV) during a recent program on CNBC. ABBV shares are up 21% so far this […]

Description: This member of dividend royalty checks off lots of boxes for investors.

Description: Opportunities in the U.S. multiple myeloma market include leveraging cutting-edge therapies like targeted treatments and immunotherapies, capitalizing on aging demographics, increasing disease awareness, and investing in oncology research. Expansion in combination treatments also offers significant potential. U.S. Multiple Myeloma Market U.S. Multiple Myeloma Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "United States Multiple Myeloma Market Size, Insights, Analysis, Growth Potential and

Description: Some might call them boring businesses, but they have tremendous dividend growth track records.

Description: The market didn't exactly greet the company's latest earnings release with open arms.

Description: AbbVie (ABBV) reported revenue growth is expected at 6.8% per year, trailing the broader US market forecast of 10.3% per year. Earnings are projected to grow at 16% per year, just ahead of the US market average. Results this year were heavily impacted by a one-off loss of $14.5 billion in the last twelve months through September 30, 2025, with net profit margins dropping to 6.4% from 9.6% a year earlier. With a high price-to-earnings ratio of 103.5x and a five-year annual earnings decline of...

Description: AbbVie leaned hard on Skyrizi, Rinvoq and Botox to offset continued steep declines from Humira, an analyst said Friday as AbbVie stock fell.

Description: AbbVie Inc (ABBV) surpasses earnings expectations with robust growth in immunology and neuroscience, despite facing significant Humira sales decline.

Description: Yahoo Finance host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute, including AbbVie (ABBV) shares sliding as the company raises its annual forecast on the success of its anti-inflammatory drugs, while Sharpie-parent company Newell Brands (NWL) stock plunges after cutting its full-year outlook on a challenging consumer environment tied to tariff price hikes. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Description: ABBV tops Q3 earnings and revenue estimates, driven by Rinvoq and Skyrizi gains, and lifts its 2025 EPS outlook.

Description: Shares of pharmaceutical company AbbVie (NYSE:ABBV) fell 3.9% in the afternoon session after the company reported third-quarter results that were overshadowed by a steep drop in profitability and a reduced earnings forecast for the full year. Although AbbVie's quarterly revenue of $15.78 billion and adjusted earnings per share (EPS) of $1.86 both surpassed Wall Street's estimates, investors focused on underlying weaknesses. The company's operating margin fell sharply to 12.1% from 26.5% a year a

Description: Find insight on Eli Lilly, Novo Nordisk, Pfizer and more in the latest Market Talks covering Health Care.

Description: The Dow was struggling to stay above breakeven despite Amazon stock’s best efforts on Friday. The blue-chip index was moving in and out of negative territory. The S&P 500 was up 0.3%. The Nasdaq Composite was up 0.

Description: All three major US stock indexes were up in late-morning trading Friday as investors digested strong

Description: Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Reddit's (RDDT) stock surging after releasing strong third quarter revenue and advertising sales forecasts, AbbVie (ABBV) shares slumping on mixed drug sales in its third quarter, and Western Digital (WDC) topping its earnings expectations. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Description: AbbVie (ABBV) raised its full-year outlook even as weakness in its Humira rheumatoid arthritis medic

Description: Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.

Description: AbbVie stock dropped Friday after the biopharmaceutical company reported mixed results across its drug portfolios in the third quarter. Shares declined 4.7% to $217.50, putting AbbVie on pace for its lowest same-day percentage decrease since May 14, according to Dow Jones Market Data. Pharma peers traded mixed: Johnson & Johnson fell slightly while Pfizer gained 0.7%.

Description: AbbVie (ABBV) delivered earnings and revenue surprises of +5.08% and +1.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: AbbVie raised its full-year adjusted earnings outlook, even though profit was pressured by increased expenses during the third quarter.

Description: Investing.com - AbbVie has lifted its annual profit guidance, after solid demand for the pharmaceutical group’s Skyrizi psoriasis drug helped third-quarter sales surpass estimates.

Description: Pharmaceutical company AbbVie (NYSE:ABBV) announced better-than-expected revenue in Q3 CY2025, with sales up 9.1% year on year to $15.78 billion. Its non-GAAP profit of $1.86 per share was 4.2% above analysts’ consensus estimates.

Description: ABBV) on Friday reported third-quarter net income of $186 million. On a per-share basis, the North Chicago, Illinois-based company said it had net income of 10 cents. Earnings, adjusted for amortization costs and asset impairment costs, were $1.86 per share.

Description: AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2025.

Description: Market Domination Overtime host Josh Lipton previews several of the biggest stories to come tomorrow, Friday, October 31, including earnings results from energy companies like Exxon Mobil (XOM), Chevron (CVX), and Dominion Energy (D), key commentary from a handful of Federal Reserve presidents, and the deadline for Disney (DIS) and YouTube (GOOG, GOOGL) to reach a new distribution deal. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.

Description: Rinvoq will have to come up against Pfizer’s prospective and Incyte’s approved JAK inhibitors in the NSV indication.

Description: Today, AbbVie (NYSE: ABBV) has announced that Canada's Drug Agency (CDA-AMC), formerly CADTH, has recommended that ELAHERE® (mirvetuximab soravtansine for injection), an antibody-drug conjugate (ADC), be reimbursed with conditions, for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.1

Description: Investors will tune into earnings from Amazon and Apple, plus the European Central Bank's interest-rate decision. Here’s what to watch for: Today Earnings: Amazon, Apple, Eli Lilly, Hershey, Mastercard Federal Reserve speaker: Vice Chair for Supervision Michelle Bowman at 9:55 a.

Description: Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting results this Friday before market open. Here’s what you need to know.

Description: If you own AbbVie stock or are thinking about adding it to your portfolio, you’ve probably noticed the ups and downs lately. After an impressive 25.5% gain so far this year, shares have cooled off a bit over the past week, dropping 1.5%. Looking at the big picture, AbbVie’s long-term run has been nothing short of remarkable, with a 189.5% climb over five years. Moves like these naturally make investors wonder if the current price reflects genuine growth potential, or if the market is simply...

Description: Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the seventh annual BOTOX® Cosmetic Day will take place on Wednesday, November 19, 2025. This holiday honors the exceptional providers and valued patients who've contributed to the continued success of BOTOX® Cosmetic. As the biggest celebration of the year, BOTOX® Cosmetic Day champions those who count on the one and only BOTOX® Cosmetic by providing exclusive offers through Allē, the aesthetic loyalty program from Allergan Aes

Description: The Trump administration is proposing changes to Food and Drug Administration guidelines that would make it less expensive for drugmakers to develop biosimilar medicines, the copycat versions of off-patent biologic drugs. Under the new draft guidance, FDA would no longer require all biosimilar manufacturers to run clinical trials of their drugs as a condition of approval. Instead, the FDA says it will look at analytical studies that can show whether or not the biosimilar matches the branded drug it seeks to copy.

Description: AbbVie (ABBV) has seen its stock tick slightly lower this week, with shares down 0.2% today but still up 3% over the past month. Investors are weighing these recent moves along with long-term double-digit returns. See our latest analysis for AbbVie. Zooming out, AbbVie’s share price return over the past year highlights the stock’s strong upward momentum, and when you factor in dividends, its total shareholder return hits an impressive 24% for the year. That outperformance, combined with...

Description: AbbVie (NYSE: ABBV) today announced positive topline results from two replicate Phase 3 studies evaluating the safety and efficacy of upadacitinib (RINVOQ®;15 mg, once daily in adult and adolescent patients living with non-segmental vitiligo (NSV).1 NSV, the most common form of vitiligo (occurring in over 90% of patients), is characterized by symmetrical and bilateral white patches on both sides of the body.2-4

Description: Key Insights Significantly high institutional ownership implies AbbVie's stock price is sensitive to their trading...

Description: Meta Platforms, Inc. (NASDAQ:META) is one of the stocks on Jim Cramer’s radar recently. A caller’s top five holdings were Meta, Microsoft, Walmart, Valero, and AbbVie, and they asked if their portfolio is diversified or not. In response, Cramer said: “Okay, so Valero, the margins are really good right now with oil versus gasoline. So […]

Description: Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.

Description: Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: ABBV's Q3 results are likely to hinge on Skyrizi and Rinvoq growth, as Humira erosion and hefty IPR&D charges are expected to pressure near-term earnings.

Description: Englander seems to have had several good reasons to aggressively buy shares of this big drugmaker.

Description: When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

Description: As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.

Description: Between growth and dividends, these companies have plenty to offer.

Description: AbbVie stock has seen its consensus analyst price target rise modestly from $232.78 to $237.48 per share. This change reflects evolving views in the wake of recent company updates. The shift is largely driven by extended product exclusivity and changing analyst sentiment tied to both opportunities and risks across AbbVie’s portfolio. Read on to learn how investors can keep pace with the latest shifts in AbbVie's narrative and stay informed about future developments. What Wall Street Has Been...

Description: Six of the world’s best AI chatbots received $10,000 to trade cryptocurrencies.The contest isn’t over yet, but most of them saw their portfolios take a beating. Why that shouldn’t be a surprise.

Description: Market Domination Overtime host Josh Lipton previews several of the biggest stories to come next week, including earnings results from Magnificent Seven companies Microsoft (MSFT), Amazon (AMZN), Apple (AAPL), Alphabet (GOOG, GOOGL), and Meta Platforms (META); Federal Reserve officials convening for their October FOMC meeting; and President Trump is meeting Chinese President Xi Jinping in South Korea as the government shutdown nears its fifth week. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.

Description: AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Description: The United States Breast Reconstruction Market is projected to grow from US$ 1.02 billion in 2024 to US$ 1.74 billion by 2033, with a CAGR of 6.1% from 2025 to 2033. Key factors driving this growth include rising breast cancer incidences and an increase in breast reconstruction surgeries. The availability of insurance coverage, such as through the Women's Health and Cancer Rights Act, enhances treatment accessibility. Technological advancements like less invasive procedures and 3D-printed implan

Description: AbbVie (ABBV) concluded the recent trading session at $228.68, signifying a -1.17% move from its prior day's close.

Description: We recently published 10 Stock News You Should Not Miss as Tom Lee Reiterates Bullish Market Outlook Amid AI Catalysts. AbbVie Inc. (NYSE:ABBV) is one of the stock news you should not miss. Jim Lebenthal from Cerity Partners said in a recent program on CNBC that he likes AbbVie amid “attractive” valuation and dividend yield. […]

Description: AbbVie recently announced positive topline results from its Phase 3b/4 SELECT-SWITCH trial, showing that Rinvoq (upadacitinib) was significantly more effective than Humira (adalimumab) in achieving low disease activity and remission for adults with moderate to severe rheumatoid arthritis who previously did not respond to a TNF inhibitor. This outcome highlights Rinvoq’s potential to become a more central immunology offering for AbbVie as Humira encounters increased biosimilar...

Description: We came across a bullish thesis on AbbVie Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.’s share was trading at $233.91 as of October 3rd. ABBV’s trailing and forward P/E were 112.65 and 16.84 respectively according to Yahoo Finance. AbbVie is advancing its oncology […]

Description: AbbVie's 30% surge in six months is powered by booming sales of Skyrizi and Rinvoq and renewed strength across oncology and neuroscience.

Description: Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Description: Who doesn't like payday? Investors can structure a portfolio that provides monthly income with this combination of three stocks.

Description: Apple's Services surge, Meta's AI push, and JPMorgan's strong capital markets results headline today's top stock research picks.

Description: New data show stronger remission rates as AbbVie shifts beyond Humira.

Description: Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced this year's grant recipients of The Confidence Project: Empowering Women Entrepreneurs. After completing a 12-week "Boostcamp" and leveraging their newfound skills to pitch their business to a panel of aesthetic entrepreneurs and Allergan Aesthetics executives, 20 entrepreneurs were selected. Each entrepreneur receives a $20,000 grant funded by BOTOX® Cosmetic.

Description: As the U.S. stock market begins the week on a high note, buoyed by gains across major indices and ongoing developments in trade and inflation data, investors are keenly observing opportunities amid economic uncertainties like the prolonged government shutdown. In this environment, identifying stocks that may be trading below their intrinsic value can offer potential for growth, making it crucial to consider factors such as financial health and market position when evaluating investment...

Description: ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.

Description: AbbVie (ABBV) announced that it has completed its acquisition of Gilgamesh Pharmaceuticals’ lead investigational candidate, bretisilocin. Bretisilocin is a novel, short-acting serotonin 5-HT2A receptor agonist and 5-HT releaser currently in Phase 2 clinical development for the treatment of patients with moderate-to-severe major depressive disorder. This next-generation 5-HT2A receptor agonist is designed to help address current development challenges observed with classic psychedelic compounds.

Description: AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin.